Partnering to provide breakthrough treatments to patients around the world suffering from rare genetic diseases

Over the years, BioMarin has grown its business and product pipeline independently as well as through strategic partnerships with individuals, research institutions and companies that offer complementary vision and expertise. Through partnerships with research scientists, universities and biopharmaceutical companies, BioMarin is finding new ways to better meet the needs of patients around the world suffering from rare genetic diseases.

The following are some of our current partners companies.

Genzyme Corporation

For the development and commercialization of Aldurazyme® (laronidase) for MPS I

Merck Serono

For the development and ex-U.S./ex-Japan/ex-Canada commercialization (pending regulatory approvals) of BioMarin's KUVAN® (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution and 6R-BH4 for other indications

If you are interested in establishing a strategic partnership with BioMarin, please contact our Business Development group at